IMR Press / EJGO / Special Issues / 1603160028945

 Breast Cancer

Section: Breast Cancer
Submission deadline: 30 April 2022
Special Issue Editors
Michael Friedrich, MD
Department of Gynecology and Obstetrics, Helios Hospital Krefeld, Krefeld, Krefeld, Germany
Interests: Minimally invasive surgery
Nicolò Bertozzi, MD
U.O.C. of Hand Surgery and Reconstructive Microsurgery Unit,Santa Chiara Hospital, Pisa, Italy
Special Issue Information

Dear Colleagues,

Breast cancer is the most common cancer and the second cause of cancer deaths worldwide. Consequentely there is an urgent need to develop new therapeutic agents and treatment strategies that are effective against this cancer. Treatment options for patients suffering from breast cancerare classicicaly based on cytotoxic chemotherapy or antiestrogen treatment. New treatment startegies are directed towards newly identified targets. Thus breast cancer treatment is getting more and more tumor type specific resulting in an improved outcome combined with new side effects.

In this special issue the authors will present the most innovative treatment strategies for breast cancer based on the molecular patholological character of the tumor like luminal A/B, triple negative and Her2 overexpressing breast cancer. Thus, innovative endocrine treatment options for example CDK 4/6 inhibitors and PI3K-inhibitors will be discussed for endocrine responsibel berast cancer. In triple negative breast cancer the importance of neoadjuvant treatment is presented combined with the newly accepted inhibition of the PDL1 pathway. In addition the meaningful results of PARP inhibition in BRCA mutated breast cancer are analyzed. For Her2 overexpressing breast cancer all treatment options of inhibiting this pathway with regard to the actual studies are presented for the neoadjuvant, adjuvant, post neoadjuvant and metastatic setting are presented. Last but not least the actual recommendations for oncologic and oncoplastic surgery including sentinel lymph node resection are discussed.

This issue should give a summary of the modern treatment strategies in breast cancer with a special aspect on the actual guidelines and recommendation of the new systemic treatment options.

Prof. Dr. Michael Friedrich and Dr. Nicolò Bertozzi

Guest Editors

Keywords
Breast cancer
Systemic treatment
Adjuvant setting
Metastatic setting
Genetic councelling
Triple negative breast cancer
Her2+ Breast cancer
Endocrine treatment
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Planned Paper (7 Papers)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to IMR Press journals will subject to peer-review before acceptance

Circulating Tumor Cells in Early Breast Cancer: Current Evidence and Perspectives

Maggie Banys-Paluchowski

Feasibility of a Reduced Rate of Frozen Section Examination for Sentinel Node Biopsy in Breast Carcinoma

Tommaso Susini

Clinical Advances in the Treatment of Hormone-receptor Positive Breast Cancer

Stefan Krämer

Treatment Progress in Triple Negative Breast Cancer

D. Saylan

Therapy Landscape in HER2-receptor Positive Breast Cancer

Dr. Med. M. Sellinger

Oncoplastic Surgery and Axillary Management in Primary Breast Cancer

 M. Friedrich

Multigene Signatures in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer

Marcus Schmidt, Katrin Almstedt

Published Paper (2 Papers)
Open Access Review
Treatment Progress in Triple Negative Breast Cancer
Stefan Krämer, Christoph Rogmans, Dilek Saylan, Dominique Friedrich, ... Michael Friedrich
Eur. J. Gynaecol. Oncol. 2022, 43(2), 341–352; https://doi.org/10.31083/j.ejgo4302040
(This article belongs to the Special Issue Breast Cancer)
24
Download
45
Views
Open Access Review
Role of sentinel node biopsy in breast cancer: a review
Maria Jesús Pla Farnós, Maria Eulalia Fernández-Montolí, Rosalía Pascal Capdevila, Amparo García Tejedor, ... Jordi Ponce Sebastià
Eur. J. Gynaecol. Oncol. 2021, 42(5), 982–995; https://doi.org/10.31083/j.ejgo4205147
(This article belongs to the Special Issue Breast Cancer)
12
Download
38
Views
Back to top